



## High expression of apoptosis protein (Api-5) in chemoresistant triple-negative breast cancers : an innovative target

Mélanie Di Benedetto

Université Paris 13 Nord | Paris 13 Nord • Inserm/Cheffe du département HSE

### Abstract:

Anti-apoptotic protein-5 (API-5) is a survival protein interacting with the protein acinus, preventing its cleavage by caspase-3 and thus inhibiting apoptosis. We studied the effect of targeting API-5 in chemoresistant triple negative breast cancers (TNBCs), to reverse chemoresistance. 78 TNBC biopsies from patients with different responses to chemotherapy were analysed for API-5 expression before any treatment. Further studies on API-5 expression and inhibition were performed on patient-derived TNBC xenografts, one highly sensitive to chemotherapies (XBC-S) and the other resistant to most tested drugs (XBC-R). In situ assessments of necrosis, cell proliferation, angiogenesis, and apoptosis in response to anti-API-5 peptide were performed on the TNBC xenografts

### Biography:

Melanie Di Benedetto has completed his PhD at the age of 27 years from Paris13 University and several Postdoctoral Studies from School of Medicine, Paris 13 and Paris 7 University. She is associated professor in Inserm U942 Laboratory. She is the Director of a biology department at technical institute of Paris13 University. She has published more than 30 papers in reputed journals

### Recent Publications:

1. MDA-MB-231 breast cancer cells overexpressing single VEGF isoforms display distinct colonisation characteristics
2. Cross-drug resistance to sunitinib induced by doxo-



3. Induction of multiple drug resistance in HMEC-I endothelial cells after long-term exposure to sunitinib
4. Transcriptome Analysis and In Vivo Activity of Fluvastatin versus Zoledronic Acid in a Murine Breast Cancer Metastasis Model
5. Distinct heparin binding sites on VEGF165 and its receptors révéle by théier interaction with a non sulfated glycoaminoglycan (NaPaC)
6. High expression of apoptosis protein (Api-5) in chemoresistant triple-negative breast cancers : an innovative target
7. La résistance aux traitements anti angiogéniques Une actualité clinique et scientifique Resistance to anti-angiogenic therapy : a clinical and scientific current issue

5th International Summit on Cancer Research and Diagnosis | March 02-03, 2020 | Paris, France

Citation: Mélanie Di Benedetto ; High expression of apoptosis protein (Api-5) in chemoresistant triple-negative breast cancers : an innovative target, Cancer 2020, Paris, France.